Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma

This study aimed to investigate the effect of oral antiviral treatment on the prognosis of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after radiofrequency (RF) ablation. Between January 2003 and December 2010, 228 patients without a history of antiviral treatment were treated wit...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2016-07, Vol.7 (30), p.47794-47807
Main Authors: Sohn, Won, Kang, Tae Wook, Choi, Sun-Kyu, Jung, Sin-Ho, Lee, Min Woo, Lim, Hyo Keun, Cho, Ju-Yeon, Shim, Sang Goon, Sinn, Dong Hyun, Gwak, Geum-Youn, Choi, Moon Seok, Lee, Joon Hyeok, Koh, Kwang Cheol, Paik, Seung Woon, Rhim, Hyunchul, Paik, Yong-Han
Format: Article
Language:English
Subjects:
Administration, Oral
Antiviral Agents - therapeutic use
Carcinoma, Hepatocellular - pathology
Carcinoma, Hepatocellular - radiotherapy
Carcinoma, Hepatocellular - virology
Catheter Ablation - methods
Female
Hepatitis B virus - isolation & purification
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - pathology
Humans
Liver Neoplasms - pathology
Liver Neoplasms - radiotherapy
Liver Neoplasms - virology
Male
Middle Aged
Neoplasm Recurrence, Local - pathology
Neoplasm Recurrence, Local - virology
Prognosis
Research Paper
Retrospective Studies
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed to investigate the effect of oral antiviral treatment on the prognosis of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after radiofrequency (RF) ablation. Between January 2003 and December 2010, 228 patients without a history of antiviral treatment were treated with RF ablation for a single HBV-related HCC. We divided the patients into two groups, patients who received (n=125) or did not receive antiviral treatment (n=103), based on whether oral antiviral treatment was administered after RF ablation. The median duration of antiviral treatment was 60.1 months. HCC recurrence and overall survival were compared in the two groups in the full cohort and the propensity score-matched cohort. In the matched cohort, the probability of HCC recurrence at 5 years was 43.8% for the non-antiviral treatment group and 14.7% for the antiviral treatment group (p
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.10026